Skip Navigation


NDT Plus Advance Access originally published online on December 18, 2008
NDT Plus 2009 2(2):152-154; doi:10.1093/ndtplus/sfn195
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2/2/152    most recent
sfn195v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Inoue, K.
Right arrow Articles by Rakugi, H.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Severe adverse effects of 5-fluorouracil in S-1 were lessened by haemodialysis due to elimination of the drug

Kazunori Inoue, Yasuyuki Nagasawa, Ryohei Yamamoto, Hiroki Omori, Tomonori Kimura, Kodo Tomida, Yoshiyuki Furumatsu, Enyu Imai, Yoshitaka Isaka and Hiromi Rakugi

Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan

Correspondence: Correspondence and offprint requests to: Kazunori Inoue, Department of Nephrology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka (B6), Suita-city, Osaka 565-0871, Japan. Tel: +81-6-6879-3632; Fax: +81-6-6879-3639; E-mail: kznri{at}kid.med.osaka-u.ac.jp


  Abstract

S-1 and cisplatin are used as one of the first-line chemotherapies for gastric cancer in Japan. The plasma concentration of 5-fluorouracil (5-FU) is increased in patients with renal dysfunction because gimeracil in S-1 inhibits the degradation of 5-FU and about 50% of gimeracil is excreted in the urine. We describe a 35-year-old man with acute kidney injury while taking S-1 and cisplatin for advanced gastric cancer and who presented severe adverse effects of 5-FU. This case report describes the evolution of the plasma concentrations of 5-FU with haemodialysis along with a decrease in the adverse drug effects.

Key Words: 5-fluorouracil • gimeracil • haemodialysis • S-1

Received for publication November 8, 2008. Accepted for publication November 24, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.